HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Intravenous amantadine for freezing of gait resistant to dopaminergic therapy: a randomized, double-blind, placebo-controlled, cross-over clinical trial.

AbstractBACKGROUND:
Freezing of gait (FOG) is one of the most disabling symptoms in Parkinsonism. Open-label studies have suggested that intravenous (IV) amantadine is effective against FOG resistant to dopaminergic therapy in Parkinson's disease (PD). We evaluated the efficacy of IV amantadine on FOG resistant to dopaminergic therapy.
METHODOLOGY/PRINCIPAL FINDINGS:
This was a randomized, double-blind, placebo-controlled, cross-over study on IV amantadine. The placebo (normal saline) and amantadine (400 mg/day) were injected for 2 days with a 52-hour washout period. The instruments for the outcome measures were the Freezing of Gait Questionnaire (FOGQ), Unified Parkinson's disease rating Scale (UPDRS), and the duration of the 4×10 m walking test. The placebo arm was compared to the amantadine arm. Ten patients were enrolled but two patients withdrew, one from each arm. The FOGQ and UPDRS scores and the duration of the 4×10 m walking test improved in both arms compared to the baseline (P<0.05 in all). However, there were no differences in these values between the amantadine arm and placebo arm (P = 0.368, P = 0.583, P = 0.206, respectively). Follow-up measures 2 weeks after discharge in an open-label study showed the beneficial effects of an amantadine tablet on FOG (FOGQ, P = 0.018; UPDRS, P = 0.012 respectively).
CONCLUSIONS/SIGNIFICANCE:
This double blind, placebo-controlled study did not show the efficacy of IV amantadine on FOG when compared with the placebo. This study provides Class II evidence due to small sample size for the lack of benefit of IV amantadine on FOG resistant to dopaminergic therapy
TRIAL REGISTRATION:
Clinicaltrials.gov NCT01313819.
AuthorsYoung Eun Kim, Ji Young Yun, Hui June Yang, Han-Joon Kim, Namyi Gu, Seo Hyun Yoon, Joo-Youn Cho, Beom S Jeon
JournalPloS one (PLoS One) Vol. 7 Issue 11 Pg. e48890 ( 2012) ISSN: 1932-6203 [Electronic] United States
PMID23185280 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Placebos
  • Amantadine
  • Dopamine
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Amantadine (administration & dosage, pharmacology, therapeutic use)
  • Cross-Over Studies
  • Dopamine (pharmacology, therapeutic use)
  • Double-Blind Method
  • Drug Resistance (drug effects)
  • Freezing Reaction, Cataleptic (drug effects)
  • Gait
  • Humans
  • Injections, Intravenous
  • Middle Aged
  • Parkinson Disease (drug therapy, physiopathology)
  • Placebos

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: